Scheduled versus Pro Re Nata dosing in the VIEW trials

Abstract

Purpose To analyze visual acuity (VA) outcomes before and after preplanned treatment regimen change in the VIEW studies at week 52 (W52). Design Multiple post hoc analyses for retrospectively defined subgroups in 2 multicenter, multinational, double-masked trials. Participants Two thousand four hundred fifty-seven neovascular age-related macular degeneration (AMD) patients. Methods Patients were randomized to treatment with 0.5 mg ranibizumab given monthly, a 0.5-mg or 2-mg intravitreal aflibercept injection given monthly, or 2 mg intravitreal aflibercept given every other month, after 3 initial monthly doses, up to W52. From W52 through W96, patients received their original dosing assignmen..